FDA staff raises efficacy doubts on GSK's lung disease treatment


U.S. Food and Drug Administration staff reviewers have raised doubts over the effectiveness of GlaxoSmithKline Plc's drug Nucala in treating a disease that limits airflow to the lungs. FILE PHOTO: The GlaxoSmithKline logo is seen on top of GSK Asia House in Singapore, March 21, 2018.



from Biotech News